

## ARCHIVIO ISTITUZIONALE DELLA RICERCA

## Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Raschi E., La Placa M., Poluzzi E., De Ponti F. (2021). The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. BRITISH JOURNAL OF DERMATOLOGY, 184(3), 581-583 [10.1111/bjd.19677].

Availability:

This version is available at: https://hdl.handle.net/11585/882216 since: 2022-04-14

Published:

DOI: http://doi.org/10.1111/bjd.19677

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version.

(Article begins on next page)

EMANUEL RASCHI (Orcid ID : 0000-0003-0487-7996)

DR MICHELANGELO LA PLACA (Orcid ID : 0000-0002-6894-3350)

Article type : Letter to the Editor

The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice

E. Raschi,<sup>1</sup> M. La Placa,<sup>2</sup> E. Poluzzi<sup>1</sup> and F. De Ponti<sup>1</sup>

<sup>1</sup> Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy

<sup>2</sup> Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum - University of Bologna, Bologna, Italy

Correspondence: Emanuel Raschi, MD, PhD

Email: emanuel.raschi@unibo.it ORCID: 0000-0003-0487-7996

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi:</u> 10.1111/BJD.19677

This article is protected by copyright. All rights reserved

We greatly appreciate a recent Editorial remarking the value of published case reports in drug safety and underlines the too often overlooked importance of reporting adverse drug reactions (i.e., adverse events suspectedly attributed to drug exposure) to a pharmacovigilance system.<sup>1</sup>

Dermatologists are facing new challenges in real-world pharmacovigilance. On one hand, skin manifestations are increasingly documented with anticancer drugs and require multidisciplinary management since cutaneous adverse events have been proposed as potential biomarkers of drug efficacy, implying a delicate balance between timely interruption of the offender (with medical treatment) and early resumption to avoid cancer recurrence or progression. A recent example includes immune checkpoint inhibitors, which may cause a variegate spectrum of skin toxicity, including rare but serious cutaneous adverse reactions, namely Stevens-Johnson syndrome, Toxic epidermal necrolysis, and Drug Rash with Eosinophilia and Systemic Symptoms.<sup>2</sup>

On the other hand, the widespread use of biologicals such as monoclonal antibodies in cutaneous diseases (e.g., psoriasis) requires new diagnostic skills to dermatologists, who should become aware of rare but potentially serious non-dermatological events such as infections, neuro-psychiatric and cardiovascular risks. In fact, these potentially innovative drugs are usually marketed through accelerated pathways, namely shortened review time and conditional approval, thus implying provisional evidence of efficacy and safety due to underpowered clinical trials and their inability to fully capture rare adverse events, strengthening the role of proactive pharmacovigilance monitoring. Examples include novel IL-17 (e.g., secukinumab, bradolumab), and IL-23 antagonists (e.g., ustekinumab, tildrakizumab), for which both acute and long-term unexpected concerns have been described (e.g., malignancies with ustekinumab). <sup>3</sup>

In this regard, pharmacovigilance databases represent an unprecedented opportunity not only to perform real-world post-marketing studies on biological medications in dermatology <sup>4</sup>, but also to provide a real-time overview of major toxicities, thus informing clinical practice for proactive monitoring. Of note, these archives mainly contain unpublished case reports and can be queried through online tools by individual researchers (**Table 1**). This is the case of the FDA Adverse Event Reporting system (FAERS), which allows: 1) data visualization and download through a public dashboard (https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-

public-dashboard); 2) access to raw data for customized analyses), namely disproportionality algorithms aiming at detecting higher-than-expected reporting of a given adverse event; 3) access to individual cases (narratives) through a direct request to the FDA. Thus, these spontaneous reporting systems can add clinical and pharmacological substantiation to case reports by detecting a potential drug-event association, also known as "signal". In line with case reports, firm causative role cannot be inferred, and signals, even when statistically robust, warrant verification through dedicated prospective research or meta-analysis to support a real association.

Notwithstanding limitations, case reports individually published or collectively gathered in spontaneous reporting systems represent a valuable and irreplaceable opportunity for real-world assessment of post-marketing safety of medications.

**Acknowledgement:** The study was not funded in whole or in part by any research grant or funding body. The authors are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).

**Conflicts of interest:** The authors declare they have no conflicts of interest.

## References

- 1. Garcia-Doval I, Segovia E, Hunter H, Frew J, Naldi L. The value of case reports in pharmacovigilance. *Br J Dermatol* 2020; **183** :795-6.
- 2. Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F. Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. *Oncologist* 2019; **24**: e1228-e31.
- Florek AG, Nardone B, Thareja S, Tran G, Giles FJ, West DP. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database. *Br J Dermatol* 2017; 177: e220-e21.
- Dequidt L, Franck N, Sanchez-Pena P, Dalle S, Adamski H, Boulinguez S, Ingen-Housz-Oro S, Ram-Wolff C, Boccara O, Bonnet N, Cortes B, Gouraud A, Grange F, Le Corre Y, Quereux G, De Masson A, Schmutz JL, Skowron F, Verneuil L, Beylot-Barry M. Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. *Br J Dermatol* 2019; **181**: 616-18.

Table 1. Overview of major international spontaneous reporting databases that can be queried through publicly available online tools.

Database	Website	Time window	Products covered	Catchment area	Search criteria
					(customization)
FDA Adverse	https://www.fda.gov/drugs/questions-	1969 (2004 for data	Medicines *	Worldwide (20 million	By medication (up to
event Reporting	and-answers-fdas-adverse-event-	download)-present		reports)	five)/reaction #
System (FAERS)	reporting-system-faers/fda-adverse-event-				Raw data can be also
	reporting-system-faers-public-dashboard				downloaded \$
WHO-Vigibase	http://www.vigiaccess.org/	1968-present	Medicines and	Worldwide (over 110	By product
			vaccines	Countries)	
Eudravigilance	http://www.adrreports.eu/en/index.html	2001-present	Medicines authorized	Europe	By product/substance
			in the European		
			Union ±		
Australian	https://www.tga.gov.au/database-	1971-present	Medicines and	Australia	By product, data range,
Database	adverse-event-notifications-daen		vaccines licensed in		organ/system/toxicity
of Adverse Event			Australia		
Notifications					
(DAEN)					
Canada Vigilance	https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-	1965-present	Medicines, vaccines	Canada	By product, date,
Adverse	eng.jsp		and health products		seriousness, demographic
Reaction			licensed in Canada		information, ADR term
Online Database					

ADR: adverse drug reaction.

± Medicines approved through non-centralized procedure are also present.

\* Devices, vaccines, and other products (e.g., food supplements) are not included, as they are specifically recorded in ad hoc databases: MAUDE—Manufacturer and User Facility Device Experience (ttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM), VAERS—Vaccines Adverse Event Reporting System (https://vaers.hhs.gov/data/datasets.html), and CAERS—Center for Food Safety and Applied Nutrition Adverse Event Reporting System (https://www.fda.gov/food/complianceenforcement/ucm494015.htm).

# Customized analyses without data download are also possible through online systems, named AERSMine (https://research.cchmc.org/aers/home) and OpenVigil http://openvigil.pharmacology.uni-kiel.de/openvigilfda.php).

\$ FAERS data can be extracted in different formats, namely download quarterly files (https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files), and APIs (https://open.fda.gov/).

This article is protected by copyright. All rights reserved